Featured Research

from universities, journals, and other organizations

Guardian of genome, targeted therapies in non-diabetic, HER2 positive breast cancer patients: Adding new dowels to a dated puzzle

Date:
July 28, 2014
Source:
Sbarro Health Research Organization (SHRO)
Summary:
Research in breast cancer has lately allowed to characterize molecular features that have increasingly become the targets for novel therapeutic interventions. Trastuzumab has revolutionized the treatment of patients with HER2 positive breast cancer. At the same time, we have gained knowledge on the importance of glucose metabolism in several tumors, including breast cancer

The study entitled "p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab" has been recently judged suitable for publication in Oncotarget and will be soon available online. The authors belong to a multidisciplinary, international team led by Dr. Maddalena Barba, researcher at the Division of Medical Oncology B, Regina Elena National Cancer Institute of Rome, Central Italy.

Related Articles


"Research in breast cancer has lately allowed to characterize molecular features that have increasingly become the targets for novel therapeutic interventions. Trastuzumab has revolutionized the treatment of patients with HER2 positive breast cancer. At the same time, we have gained knowledge on the importance of glucose metabolism in several tumours, including breast cancer" says Prof. Antonio Giordano, an internationally renowned oncologist engaged for years in the fight against breast cancer.

"Within our research pipeline focused on the metabolism and cancer, we have now provided novel evidence on a widely used biomarker, namely, p53 immunostaining, as a bridging element between a systemic indicator of the glycemic body asset (fasting glucose) and treatment outcomes in non diabetic, HER2 positive breast cancer patients treated with trastuzumab" adds Prof. Giordano.

"To the best of our knowledge, the hypothesis of a role of p53 in affecting the association between pre-treatment fasting glucose and breast cancer outcomes has neither been formulated nor (been) tested before in the clinical setting. The characterization of p53 status might contribute to better define the target population and interpret treatment outcomes for interventions based on trastuzumab administration in non diabetic patients and inform decisions on co-interventions targeting glucose metabolism" clarifies Dr Barba.

"In case of confirmatory findings from future studies in similarly characterized patients, it is conceivable that lifestyle-related and pharmacological co-interventions acting on glucose metabolism in women receiving trastuzumab might possibly increase treatment efficacy and translate into improved survival" concludes Prof. Giordano.


Story Source:

The above story is based on materials provided by Sbarro Health Research Organization (SHRO). Note: Materials may be edited for content and length.


Journal Reference:

  1. Patrizia Vici et al. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget, June 2014

Cite This Page:

Sbarro Health Research Organization (SHRO). "Guardian of genome, targeted therapies in non-diabetic, HER2 positive breast cancer patients: Adding new dowels to a dated puzzle." ScienceDaily. ScienceDaily, 28 July 2014. <www.sciencedaily.com/releases/2014/07/140728104506.htm>.
Sbarro Health Research Organization (SHRO). (2014, July 28). Guardian of genome, targeted therapies in non-diabetic, HER2 positive breast cancer patients: Adding new dowels to a dated puzzle. ScienceDaily. Retrieved December 17, 2014 from www.sciencedaily.com/releases/2014/07/140728104506.htm
Sbarro Health Research Organization (SHRO). "Guardian of genome, targeted therapies in non-diabetic, HER2 positive breast cancer patients: Adding new dowels to a dated puzzle." ScienceDaily. www.sciencedaily.com/releases/2014/07/140728104506.htm (accessed December 17, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, December 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com
Yoga Could Be As Beneficial For The Heart As Walking, Biking

Yoga Could Be As Beneficial For The Heart As Walking, Biking

Newsy (Dec. 17, 2014) Yoga can help your weight, blood pressure, cholesterol and heart just as much as biking and walking does, a new study suggests. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins